News

Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) are seeing explosive gains in Tuesday's trading following an announcement that the company is on track to be acquired by Alfasigma, a private

Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for hereditary afflictions that have so far

Abbott Laboratories (NYSE: ABT) is seen as a solid safe-harbor stock because of the company's 135-year history, its diversified healthcare business, and its reliable dividend.

The company is known

Pharmaceutical giant Merck (NYSE: MRK) has delivered excellent returns to its shareholders over the past 12 months, as last year's downturn did little to slow the drugmaker. The company's solid

Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The clinical-stage bio

Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The clinical-stage bio

Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The clinical-stage bio

Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. The decline

Stock valuations are at historically high levels. However, that doesn't mean you can't find stocks worth buying.

Three Motley Fool contributors identified bargain stocks to buy in a market that's

If you're an income investor, you may have heard tales of mighty companies that have raised their payouts no matter the economic cycle. Only 49 companies over the past 50 years have managed to

Dividends are great. They're a reliable source of passive income for retirees (and others) or can help boost long-term returns for investors who choose to reinvest them. But what happens when a

Dividends are great. They're a reliable source of passive income for retirees (and others) or can help boost long-term returns for investors who choose to reinvest them. But what happens when a

Dividends are great. They're a reliable source of passive income for retirees (and others) or can help boost long-term returns for investors who choose to reinvest them. But what happens when a

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

As the United

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech

The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech